In order to support pharmaceutical development and related research initiatives, SZALONGEVITY
and King's College London have engaged into a multi-year cooperation partnership.

In order to support pharmaceutical
development and related research
initiatives, SZALONGEVITY and
King's College London have
engaged into a multi-year
cooperation partnership.

November 8, 2021

SZALONGEVITYhas entered into a multi-year collaborative agreement with King’s College London to provide multi-omics services in support of drug development and related research efforts.

SZALONGEVITY will leverage its proprietary platform to analyze a range of biological samples to accelerate research, drug development, and precision medicine. “SZALONGEVITY is proud to contribute to research to help accelerate important discoveries that could improve human health,” says Prof. Ahmet Tarik Baykal, General Manager, SZALONGEVITY.

“Multi-omics is an essential element of the scientific approach that is being employed by King’s College London to transform healthcare by understanding disease progression and therapeutic response more deeply.”

Through this collaboration, SZALONGEVITY will perform multi-omics analysis and provide a biological interpretation of results for large-scale population health initiatives, with the goal of accelerating King’s College London research and drug development initiatives.','SZALONGEVITY Collaborates with King’s College London to Enable Novel Discoveries and Accelerate Clinical Trials.','Quickly coordinate e-business applications through revolutionary catalysts for change. Seamlessly underwhelm optimal testing procedures processes. Capitalize on low hanging fruit to identify a ballpark value added activity to beta test. Override the digital